Amarin files suit against AstraZeneca over Epanova

5 March 2014

US biotech firm Amarin (Nasdaq: AMRN) revealed in a Stock Exchange Commission submission that it has filed a complaint in the US District Court for the District of Delaware against Omthera Pharmaceuticals and its parent company, Anglo-Swedish drug major AstraZeneca (LSE: AZN).

The suit seeks injunctive relief and monetary damages for infringement of Amarin’s US Patent No 8,663,662, which was issued by the US Patent and Trademark Office this week.

The complaint alleges infringement of the patent arising from the expected launch of Epanova (a novel omega-3 free fatty acid composition) in the USA. The patent covers methods of lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. Epanova could compete with Amarin's triglyceride therapy Vascepa (icosapent ethyl). Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights, the company said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK